I'm hiring a CMC Regulatory Lead to drive CMC Regulatory strategy and execution at Retro. This is an opportunity to join a fast-rising, early-stage biotech backed by Sam Altman that is developing therapeutics that target the fundamental drivers of aging to treat and prevent multiple downstream age-related diseases. Our pipeline is unusually broad for a company at our stage: cell and gene therapies, small molecules, and AI-designed protein therapeutics. For someone who loves the craft of CMC regulatory work, this is a chance to work at real technical depth across multiple therapeutic modalities and help build something important. jobs.lever.co/retro/2f9b3bc9…

really enjoyed being a part of this conversation - with therapies now starting to target the upstream cause (aging) of multiple downstream serious diseases, there is so much opportunity for us to unlock over the next decade some things worth considering: non-legislative - an FDA center of excellence for healthspan products - application of accelerated approval to therapies targeting age-related diseases and multimorbidity legislative - Multi-Disease Therapeutic Designation to enable cross-division communication with FDA for multimorbidity registrational plans - THRIVE Act tiered-approval approach for healthspan products